Document
false0001090872 0001090872 2020-08-18 2020-08-18
 
 
 






UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 18, 2020
 
AGILENT TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter)
 
 
Delaware
 
 

001-15405
 
 

77-0518772
 
(State or other jurisdiction
 
(Commission
 
(IRS Employer
of incorporation)
 
File Number)
 
Identification No.)
 
5301 Stevens Creek Boulevard, Santa Clara, CA 95051
(Address of Principal Executive Offices) (Zip Code)
 
Registrant’s telephone number, including area code (800) 227-9770
 
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
 
TITLE OF EACH CLASS
 
 
TRADING SYMBOL(S)
 
NAME OF EACH EXCHANGE ON WHICH REGISTERED

COMMON STOCK, $0.01 PAR VALUE
 
 

A
 
 

New York Stock Exchange
 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  


 
 
 



Item 2.02.              Results of Operations and Financial Condition.
 
The information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
 
On August 18, 2020, Agilent Technologies, Inc. (the “Company”) issued its press release announcing financial results for the third fiscal quarter ended July 31, 2020.  A copy of this press release is attached as Exhibit 99.1.
 
The Company provides non-GAAP financial information in order to provide meaningful supplemental information regarding its operational performance and to enhance its investors’ overall understanding of its core current financial performance and its prospects for the future.  The Company believes that its investors benefit from seeing its results “through the eyes” of management in addition to the GAAP presentation.  Management measures segment and enterprise performance using measures such as those that are disclosed in this release.  This information facilitates management’s internal comparisons to the Company’s historical operating results and comparisons to competitors’ operating results.  Non-GAAP information allows for greater transparency to supplemental information used by management in its financial and operations decision making.  Historically, the Company has reported similar non-GAAP information to its investors and believes that the inclusion of comparative numbers provides consistency in its financial reporting.
 
This information is not in accordance with, or an alternative for, generally accepted accounting principles in the United States.  It excludes items, such as restructuring and amortization, that may have a material effect on the Company’s expenses and earnings per share calculated in accordance with GAAP.  Management monitors these items to ensure that expenses are in line with expectations and that the Company's GAAP results are correctly stated but does not use them to measure the ongoing operating performance of the Company.  The non-GAAP information the Company provides may be different from the non-GAAP information provided by other companies.
 
Additional explanation of non-GAAP information is provided in Exhibit 99.1.


Item 9.01.              Financial Statements and Exhibits.
 
(d) Exhibits
 
The following is furnished as an exhibit to this report and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended:
 
Exhibit No.
 
Description
 
 
 

 
Press release announcing financial results for the third fiscal quarter ended July 31, 2020
104

 
Cover page interactive data file (embedded within the Inline XBRL document)




2

 
 
 



SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
AGILENT TECHNOLOGIES, INC.
 
 
 
 
 
By:
/s/ P. Diana Chiu
 
Name:
P. Diana Chiu
 
Title:
Vice President, Assistant General Counsel
and Assistant Secretary
 
 
 
 
 
 
 
Date: August 18, 2020
 







3

 
 
 
Exhibit



Exhibit 99.1


Agilent Reports Third-Quarter Fiscal Year 2020 Financial Results
Highlights:
Revenue of $1.26 billion represents decline of 1% reported growth year-over-year, down 3.1% on a core(1) basis
GAAP net income of $199 million, or 64 cents per share
Non-GAAP(2) net income of $243 million, or 78 cents per share
SANTA CLARA, California, Aug. 18, 2020 - Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.26 billion for the third quarter ended July 31, 2020, a decline of 1% compared to the third quarter of 2019 and down 3.1% on a core(1) basis.
Third-quarter GAAP net income was $199 million, or 64 cents per share. This compares with $191 million, or 60 cents per share, in the third quarter of fiscal year 2019. Non-GAAP(2) net income was $243 million, or 78 cents per share, during the quarter compared with $240 million, or 76 cents per share, during the third quarter a year ago.
“Agilent’s third quarter results once again highlight the strength and resilience of the Agilent team and of our business,” said Mike McMullen, Agilent president and CEO. “Under challenging conditions created by the global COVID-19 pandemic, Agilent again delivered strong results. While the world’s economies are expected to recover at different rates in the fourth quarter, we remain focused on growth and investing for the future, while effectively managing expenses.”
Financial Highlights
Life Sciences and Applied Markets Group
Third-quarter revenue of $557 million from Agilent’s Life Sciences and Applied Markets Group (LSAG) was up 2% year over year (down 4% on a core(1) basis). LSAG’s operating margin was 22.6%.
Agilent CrossLab Group
Third-quarter revenue of $463 million from the Agilent CrossLab Group (ACG) declined 1% year over year (up 1% on a core(1) basis). ACG’s operating margin was 28.4%.
Diagnostics and Genomics Group
Third-quarter revenue of $241 million from Agilent’s Diagnostics and Genomics Group (DGG) declined 8% year over year (down 8% on a core(1) basis). DGG’s operating margin was 17.2%.
Conference Call
Agilent’s management will present additional details regarding the company’s third-quarter 2020 financial results on a conference call with investors today at 1:30 p.m. PST. This event will be webcast live in listen-only mode. To listen to the webcast, select the “Q3 2020 Agilent Technologies Inc. Earnings Conference Call” link in the “News & Events -- Events” portion of the Investor Relations section of the Agilent website. The webcast will remain on the company site for 90 days.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedInTwitter, and Facebook.
Forward-Looking Statements
This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding Agilent’s growth prospects, business model and financial results and the impact of COVID-19. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of Agilent’s customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing, and the risk that Agilent is not able to realize the savings expected from integration and restructuring activities. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that its cost-cutting initiatives will impair its ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on its operations, its markets and its ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of its supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; the adverse impacts of and risks posed by the COVID-19 pandemic and other risks detailed in Agilent’s filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the quarter ended April 30, 2020. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.
(1) Core revenue growth excludes the impact of currency and acquisitions and divestitures within the past 12 months. Core revenue is a non-GAAP measure. A reconciliation between Q3 FY20 GAAP revenue and core revenue is set forth on page 6 of the attached tables along with additional information regarding the use of this non-GAAP measure.
(2) Non-GAAP net income and non-GAAP earnings per share primarily exclude the impacts of non-cash asset impairments, intangibles amortization, transformational initiatives and acquisition and integration costs. Agilent also excludes any tax benefits or expenses that are not directly related to ongoing operations and which are either isolated or are not expected to occur again with any regularity or predictability. A reconciliation between non-GAAP net income and GAAP net income is set forth on page 4 of the attached tables along with additional information regarding the use of this non-GAAP measure.
# # # # #
INVESTOR CONTACT:                        
Ankur Dhingra                            
+1 408-345-8948                        
ankur_dhingra@agilent.com                    

MEDIA CONTACT:
Tom Beermann
+1 408-553-2914
tom.beermann@agilent.com



1



AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY
 
 
 
Three Months Ended
 
Nine Months Ended
 
 
 
July 31
 
July 31
 
 
 
2020
 
2019
 
2020
 
2019
 
 
 
 
 
 
 
 
 
 
 
Net revenue
 
$
1,261

 
$
1,274

 
$
3,856

 
$
3,796

 
 
 
 
 
 
 
 
 
 
 
Costs and expenses:
 
 
 
 
 
 
 
 
 
Cost of products and services
 
592

 
582

 
1,807

 
1,728

 
Research and development
 
92

 
101

 
393

 
302

 
Selling, general and administrative
 
347

 
366

 
1,109

 
1,075

 
Total costs and expenses
 
1,031

 
1,049

 
3,309

 
3,105

 
 
 
 
 
 
 
 
 
 
 
Income from operations
 
230

 
225

 
547

 
691

 
 
 
 
 
 
 
 
 
 
 
Interest income
 
1

 
10

 
7

 
30

 
Interest expense
 
(19
)
 
(18
)
 
(59
)
 
(53
)
 
Other income (expense), net
 
7

 
5

 
64

 
20

 
 
 
 
 
 
 
 
 
 
 
Income before taxes
 
219

 
222

 
559

 
688

 
 
 
 
 
 
 
 
 
 
 
Provision (benefit) for income taxes
 
20

 
31

 
62

 
(189
)
 
 
 
 
 
 
 
 
 
 
 
Net income
 
$
199

 
$
191

 
$
497

 
$
877

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income per share:
 
 
 
 
 
 
 
 
 
Basic
 
$
0.64

 
$
0.61

 
$
1.61

 
$
2.78

 
Diluted
 
$
0.64

 
$
0.60

 
$
1.59

 
$
2.74

 
 
 
 
 
 
 
 
 
 
 
Weighted average shares used in computing net income per share:
 
 
 
 
 
 
 
 
 
Basic
 
309

 
312

 
309

 
316

 
Diluted
 
312

 
316

 
312

 
320

 
 
 
 
 
 
 
 
 
 
 




The preliminary income statement is estimated based on our current information.


1



AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(In millions, except par value and share amounts)
(Unaudited)
PRELIMINARY
 
 
July 31,
2020
 
October 31,
2019
ASSETS
 
 

 
 

Current assets:
 
 

 
 

Cash and cash equivalents
 
$
1,358

 
$
1,382

Accounts receivable, net
 
930

 
930

Inventory
 
746

 
679

Other current assets
 
211

 
198

Total current assets
 
3,245

 
3,189

 
 
 
 
 
Property, plant and equipment, net
 
846

 
850

Goodwill and other intangible assets, net
 
4,482

 
4,700

Long-term investments
 
148

 
102

Other assets
 
825

 
611

Total assets
 
$
9,546

 
$
9,452

 
 
 
 
 
LIABILITIES AND EQUITY
 
 

 
 

 
 
 
 
 
Current liabilities:
 
 

 
 

Accounts payable
 
$
311

 
$
354

Employee compensation and benefits
 
306

 
334

Deferred revenue
 
397

 
336

Short-term debt
 
40

 
616

Other accrued liabilities
 
260

 
440

Total current liabilities
 
1,314

 
2,080

 
 
 
 
 
Long-term debt
 
2,283

 
1,791

Retirement and post-retirement benefits
 
355

 
360

Other long-term liabilities
 
613

 
473

Total liabilities
 
4,565

 
4,704

 
 
 
 
 
Total Equity:
 
 

 
 

Stockholders' equity:
 
 

 
 

Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding
 

 

Common stock; $0.01 par value; 2 billion shares authorized; 309 million shares at July 31, 2020 and 309 million shares at October 31, 2019, issued
 
3

 
3

Additional paid-in-capital
 
5,324

 
5,277

Retained earnings (accumulated deficit)
 
130

 
(18
)
Accumulated other comprehensive loss
 
(476
)
 
(514
)
Total stockholders' equity
 
4,981

 
4,748

Total liabilities and equity
 
$
9,546

 
$
9,452

 


The preliminary balance sheet is estimated based on our current information.

2



AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(In millions)
(Unaudited)
PRELIMINARY
 
 
Nine Months Ended
 
 
July 31,
 
 
2020
 
2019
Cash flows from operating activities:
 
 

 
 
Net income
 
$
497

 
$
877

Adjustments to reconcile net income to net cash provided by (used in) operating activities:
 
 
 
 
Depreciation and amortization
 
232

 
162

Share-based compensation
 
63

 
57

Excess and obsolete inventory related charges
 
18

 
12

Asset impairment charges
 
99

 

Unrealized gain on equity securities
 
(26
)
 
(1
)
Other non-cash (income) expenses, net
 
6

 
5

Changes in assets and liabilities:
 
 
 
 
Accounts receivable, net
 
1

 
(58
)
Inventory
 
(86
)
 
(31
)
Accounts payable
 
(35
)
 

Employee compensation and benefits
 
(32
)
 
(35
)
Other assets and liabilities
 
(193
)
 
(281
)
Net cash provided by operating activities (a)
 
544

 
707

 
 
 
 
 
Cash flows from investing activities:
 
 
 
 
Investments in property, plant and equipment
 
(92
)
 
(125
)
Proceeds from sale of property, plant and equipment
 
1

 

Payment to acquire fair value investments
 
(20
)
 
(21
)
Payment in exchange for convertible note
 
(9
)
 
(2
)
Payment to acquire intangible assets
 

 
(1
)
Acquisition of businesses and intangible assets, net of cash acquired
 

 
(248
)
Net cash used in investing activities
 
(120
)
 
(397
)
 
 
 
 
 
Cash flows from financing activities:
 
 
 
 
Issuance of common stock under employee stock plans
 
56

 
52

Payment of taxes related to net share settlement of equity awards
 
(34
)
 
(15
)
Payment of dividends
 
(167
)
 
(155
)
Issuance of senior notes
 
499

 

Debt issuance costs
 
(4
)
 

Proceeds from revolving credit facility
 
798

 

Repayment of revolving credit facility and short-term loan
 
(1,413
)
 

Proceeds from commercial paper
 
240

 

Repayment of commercial paper
 
(200
)
 

Repayment of finance lease
 
(4
)
 

Purchase of non-controlling interest
 

 
(4
)
Treasury stock repurchases
 
(219
)
 
(674
)
Net cash used in financing activities
 
(448
)
 
(796
)
 
 
 
 
 
Effect of exchange rate movements
 

 
3

 
 
 
 
 
Net decrease in cash, cash equivalents and restricted cash
 
(24
)
 
(483
)
 
 
 
 
 
Cash, cash equivalents and restricted cash at beginning of period
 
1,388

 
2,254

 
 
 
 
 
Cash, cash equivalents and restricted cash at end of period
 
$
1,364

 
$
1,771

 
 
 
 
 
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet:
 
 
 
 
 
 
 
   Cash and cash equivalents
 
$
1,358

 
$
1,765

   Restricted cash, included in other assets
 
6

 
6

   Total cash, cash equivalents and restricted cash
 
$
1,364

 
$
1,771

 
 
 
 
 
(a) Cash payments included in operating activities:
 
 
 
 
Income tax payments (refunds), net
 
$
325

 
$
108

Interest payments
 
$
53

 
$
61


The preliminary cash flow is estimated based on our current information.

3



AGILENT TECHNOLOGIES, INC.
NON-GAAP NET INCOME AND DILUTED EPS RECONCILIATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY 
 
 
Three Months Ended
 
Nine Months Ended
 
 
July 31
 
July 31
 
 
2020
Diluted
EPS
 
2019
Diluted
EPS
 
2020
Diluted
EPS
 
2019
Diluted
EPS
GAAP net income
 
$
199

$
0.64

 
$
191

$
0.60

 
$
497

$
1.59

 
$
877

$
2.74

Non-GAAP adjustments:
 
 
 
 
 
 
 
 
 
 
 
 
Asset impairments
 


 


 
99

0.32

 


Intangible amortization
 
45

0.15

 
25

0.08

 
139

0.45

 
79

0.25

Transformational initiatives
 
13

0.04

 
11

0.03

 
41

0.13

 
25

0.08

Acquisition and integration costs
 
9

0.03

 
12

0.04

 
33

0.11

 
32

0.10

NASD site costs
 


 
6

0.02

 


 
12

0.04

Special compliance costs
 


 
1


 


 
2

0.01

Acceleration of share-based compensation expense
 
1


 


 
1


 
 
 
Other
 
1


 
11

0.03

 
(22
)
(0.07
)
 
17

0.05

Tax benefit on intra-entity asset transfer
 


 


 


 
(299
)
(0.93
)
Adjustment for taxes (a)
 
(25
)
(0.08
)
 
(17
)
(0.04
)
 
(70
)
(0.23
)
 
(33
)
(0.11
)
Non-GAAP net income
 
$
243

$
0.78

 
$
240

$
0.76

 
$
718

$
2.30

 
$
712

$
2.23


(a) The adjustment for taxes excludes tax benefits that management believes are not directly related to on-going operations and which are either isolated or cannot be expected to occur again with any regularity or predictability. For the three and nine months ended July 31, 2020, management used a non-GAAP effective tax rate of 15.50%. For the three and nine months ended July 31, 2019, management used a non-GAAP effective tax rate of 16.67% and 16.75%, respectively.

We provide non-GAAP net income and non-GAAP net income per share amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to amortization of intangibles, transformational initiatives, acquisition and integration costs, NASD site costs, special compliance costs, acceleration of share-based compensation expense and tax benefit on intra-entity asset transfer.

Asset impairments include assets that have been written down to their fair value.

Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers including costs to move manufacturing due to new tariffs and tariff remediation actions, small site consolidations, legal entity and other business reorganizations, insourcing or outsourcing of activities. Such costs may include move and relocation costs, one-time termination benefits and other one-time reorganization costs. Included in this category are also expenses associated with company programs to transform our product lifecycle management (PLM) system, human resources and financial systems.

Acquisition and integration costs include all incremental expenses incurred to effect a business combination. Such acquisition costs may include advisory, legal, accounting, valuation, and other professional or consulting fees. Such integration costs may include expenses directly related to integration of business and facility operations, the transfer of assets and intellectual property, information technology systems and infrastructure and other employee-related costs.

NASD site costs include all the costs related to the expansion of our manufacturing of nucleic acid active pharmaceutical ingredients incurred prior to the commencement of commercial manufacturing.

Special compliance costs include costs associated with transforming our processes to implement new regulations such as data privacy regulations, revenue recognition, lease accounting and certain tax reporting requirements.

Acceleration of share-based compensation expense represents stock-based compensation expense that was accelerated upon employees' involuntary termination from the company.

Other includes certain legal costs and settlements and unrealized gains related to our equity securities in addition to other miscellaneous adjustments.

Tax benefit on intra-entity asset transfer relates to our operations in Singapore along with our application of the new accounting rules for income tax consequences of intra-entity transfer of assets as adopted on November 1, 2018.

Our management uses non-GAAP measures to evaluate the performance of our core businesses, to estimate future core performance and to compensate employees. Since management finds this measure to be useful, we believe that our investors benefit from seeing our results “through the eyes” of management in addition to seeing our GAAP results. This information facilitates our management’s internal comparisons to our historical operating results as well as to the operating results of our competitors.

Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company’s profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company’s performance.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary non-GAAP net income and diluted EPS reconciliation is estimated based on our current information.

4



AGILENT TECHNOLOGIES, INC.
SEGMENT INFORMATION
(In millions, except where noted)
(Unaudited)
PRELIMINARY

Life Sciences and Applied Markets Group
 
 
Q3'20
 
Q3'19
Revenues
 
$
557

 
$
544

Gross Margin, %
 
59.3
%
 
60.5
%
Income from Operations
 
$
126

 
$
118

Operating margin, %
 
22.6
%
 
21.7
%

Diagnostics and Genomics Group
 
 
Q3'20
 
Q3'19
Revenues
 
$
241

 
$
263

Gross Margin, %
 
49.8
%
 
55.7
%
Income from Operations
 
$
41

 
$
50

Operating margin, %
 
17.2
%
 
19.1
%
 
Agilent CrossLab Group
 
 
Q3'20
 
Q3'19
Revenues
 
$
463

 
$
467

Gross Margin, %
 
52.6
%
 
52.1
%
Income from Operations
 
$
132

 
$
122

Operating margin, %
 
28.4
%
 
26.2
%


 

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, NASD site costs, special compliance costs and acceleration of share-based compensation expense.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary segment information is estimated based on our current information.

5



AGILENT TECHNOLOGIES, INC.
RECONCILIATION OF REVENUE BY SEGMENT EXCLUDING
ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)
(In millions)
(Unaudited)
PRELIMINARY
 
 
Year-over-Year
 




 
 
 
 
 
GAAP
 
 
 
 
 
GAAP Revenue by Segment
Q3'20
Q3'19
Year-over-Year
% Change
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Life Sciences and Applied Markets Group
$
557

$
544

2%
 
 
 
 
 
Diagnostics and Genomics Group
241

263

(8)%
 
 
 
 
 
Agilent CrossLab Group
463

467

(1)%
 
 
 
 
 
Agilent
$
1,261

$
1,274

(1)%
 

 
 
 
 
 
 
 
 
 
 
 
 
 
Non-GAAP
(excluding Acquisitions and Divestitures)
 
Year-over-Year at Constant Currency (a)
 
 
Non-GAAP Revenue by Segment
Q3'20
Q3'19
Year-over-Year
% Change
 
Year-over-Year % Change
Percentage Point Impact from Currency
 
Current Quarter Currency Impact (b)
 
 
 
 
 
 
 
 
 
Life Sciences and Applied Markets Group
$
513

$
544

(6)%
 
(4)%
-2 ppts
 
$
(6
)
Diagnostics and Genomics Group
241

263

(8)%
 
(8)%
 
(2
)
Agilent CrossLab Group
463

467

(1)%
 
1%
-2 ppts
 
(8
)
Agilent (Core)
$
1,217

$
1,274

(4)%
 
(3)%
-1 ppt
 
$
(16
)
 
 
 
 
 
 
 
 
 
 
.
We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

(a) The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter, and then using those revised values to calculate the year-over-year percentage change.

(b) The dollar impact from the current quarter currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.

6
v3.20.2
Document and Entity Information Document
Aug. 18, 2020
Document and Entity Information [Abstract]  
Entity Central Index Key 0001090872
Title of 12(b) Security COMMON STOCK, $0.01 PAR VALUE
Entity Incorporation, State or Country Code DE
Document Type 8-K
Document Period End Date Aug. 18, 2020
Entity Registrant Name AGILENT TECHNOLOGIES, INC.
Entity Tax Identification Number 001-15405
Entity Tax Identification Number 77-0518772
Entity Address, Address Line One 5301 Stevens Creek Boulevard
Entity Address, City or Town Santa Clara
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95051
City Area Code (800)
Local Phone Number 227-9770
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Trading Symbol A
Security Exchange Name NYSE
Amendment Flag false